In a phase-I clinical trial the monoclonal antibody BW 494/32 was administered to 18 patients with advanced pancreatic cancer of ductal origin. This murine immunoglobulin mediates an ADCC. The majority of patients tolerated this treatment without any side effects. There were no tumor remissions. 12 patients showed a progression of their pancreatic carcinoma after therapy. A stable course of the disease was observed in 6 patients for at least 3 months after therapy.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
pancreatic carcinoma
8
monoclonal antibody
8
antibody 494/32
8
[therapy pancreatic
4
carcinoma monoclonal
4
494/32 clinical
4
clinical results]
4
results] phase-i
4
phase-i clinical
4
clinical trial
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!